Antimicrobial Agents Practice Questions

Q: Which macrolide is MOST active against Mycobacterium leprae?

Clarithromycin. **Correct: Clarithromycin** - **Clarithromycin** is the most active macrolide against **Mycobacterium leprae**, with significant in-vitro and in-vivo bactericidal activity - It is a preferred macrolide for leprosy treatment, particularly useful as an alternative in multidrug therapy (MDT) regimens - Its efficacy is attributed to its ability to attain **high intracellular concentrations** and effectively inhibit mycobacterial protein synthesis - Superior to other macrolides in terms of potency against *M. leprae* *Incorrect: Azithromycin* - While **azithromycin** possesses some activity against *M. leprae*, its potency is **less than clarithromycin** - It has a longer half-life and good tissue penetration, but is not the most active macrolide for this indication - Sometimes used in leprosy regimens, but not typically cited as the most active macrolide *Incorrect: Roxithromycin* - **Roxithromycin** has demonstrated some activity against *M. leprae* in laboratory settings, but is **not as extensively studied or commonly used** as clarithromycin for leprosy - Its clinical utility for leprosy is less well-established - Not considered first-line among macrolides for this indication *Incorrect: Erythromycin* - **Erythromycin**, the first macrolide discovered, has **limited activity** against *M. leprae* compared to newer macrolides like clarithromycin - Poor bioavailability and more frequent dosing requirements make it less practical - Not considered a primary agent for the treatment of leprosy

Q: For systemic mycosis, fluconazole is preferred over ketoconazole because of:

All of the options. ***All of the options*** Fluconazole is preferred over ketoconazole for systemic mycoses due to multiple superior pharmacological properties: **Greater Efficacy:** - Fluconazole has **excellent bioavailability** (>90% oral) and superior tissue penetration, especially into the CNS and CSF - Highly effective against **Candida species** (including systemic candidiasis) and **Cryptococcus neoformans** (cryptococcal meningitis) - Ketoconazole has poor CNS penetration, making it unsuitable for deep-seated infections **Longer Half-life (t1/2):** - Fluconazole has a **half-life of ~30 hours**, enabling **once-daily dosing** - Ketoconazole has a half-life of ~8 hours, requiring multiple daily doses - Longer half-life improves patient compliance and maintains therapeutic drug levels **Lesser Side Effects:** - Fluconazole has **minimal hepatotoxicity** and is generally well-tolerated - Ketoconazole causes **significant hepatotoxicity** (black box warning) and **endocrine disturbances** by blocking steroid synthesis (gynecomastia, decreased testosterone, adrenal suppression) - Fluconazole does not interfere with steroid hormone synthesis at therapeutic doses **Clinical Practice:** Due to these combined advantages, ketoconazole is now rarely used for systemic mycoses and is primarily reserved for topical applications or specific resistant dermatophyte infections.

Q: Which is the fastest acting anti-malarial drug?

Artether. ***Artether*** - **Artether** is an artemisinin derivative known for its rapid action due to its ability to quickly reduce **parasite biomass**. - It works by producing **free radicals** that damage parasite proteins and membranes, leading to rapid parasitic clearance. *Chloroquine* - **Chloroquine** is a 4-aminoquinoline that works by inhibiting **heme detoxification** in the parasite, but its action is slower compared to artemisinins. - Due to widespread resistance, its efficacy is limited in many regions. *Quinine* - **Quinine** is an alkaloid with proven efficacy and acts by interfering with the parasite's **heme polymerization**. - While effective, its onset of action is not as rapid as that of artemisinin derivatives. *Mefloquine* - **Mefloquine** is a quinoline-methanol derivative used for malaria treatment and prophylaxis. - It has a long half-life and is effective, but its action is slower and it is not considered a rapid-acting drug.

Q: Mechanism of action of Niclosamide is:

Inhibition of mitochondrial oxidative phosphorylation. ***Inhibition of mitochondrial oxidative phosphorylation*** - **Niclosamide** is an **uncoupler of oxidative phosphorylation**, leading to **ATP depletion** in the parasite. - This effectively starves the parasite of energy, particularly **tapeworms**, which are highly dependent on this pathway. *Inhibition of substrate level phosphorylation* - **Substrate-level phosphorylation** is a metabolic pathway that directly phosphorylates ADP to ATP using high-energy intermediate molecules, not the primary target of niclosamide. - While it contributes to ATP production, its inhibition is not the primary mechanism of action for **niclosamide**. *Inhibition of proton efflux pumps* - **Proton efflux pumps** (e.g., proton pumps in gastric cells) are generally not the direct target for anthelmintic drugs like niclosamide. - This mechanism is characteristic of drugs like **proton pump inhibitors** (PPIs) used to reduce stomach acid. *Increase production of free radicals* - Some antiparasitic drugs act by increasing **oxidative stress** and **free radical production**, leading to parasite death. - However, for **niclosamide**, the primary mechanism is the disruption of **ATP synthesis** through uncoupling.

Q: Mechanism of action of Linezolid is

Inhibits peptide bond formation. ***Inhibits peptide bond formation*** - Linezolid is an **oxazolidinone antibiotic** that acts at the **initiation stage of bacterial protein synthesis**. - It binds to the **23S ribosomal RNA** of the 50S subunit, preventing formation of the **70S initiation complex** and thereby **blocking the formation of the first peptide bond**. - This is the **functional mechanism** that defines its antibacterial action. *Inhibits 30S ribosomal subunit* - This mechanism is characteristic of **aminoglycosides** (e.g., gentamicin) and **tetracyclines**, which target the 30S ribosomal subunit. - Linezolid specifically targets the **50S subunit**, not the 30S subunit. *Inhibits 23S ribosome subunit of 50S ribosome* - While this correctly describes Linezolid's **binding site** (23S rRNA of the 50S subunit), it does not specify the **functional consequence** of this binding. - The **mechanism of action** in pharmacology refers to the functional effect, which is **inhibition of peptide bond formation** at the initiation stage. - This option describes "where" the drug acts rather than "what" it does at that site. *Inhibits tRNA translocation on the ribosome* - This is the mechanism of **macrolides** (e.g., erythromycin, azithromycin) and **chloramphenicol**, which block the translocation of peptidyl-tRNA from the A-site to the P-site. - Linezolid acts at the **initiation phase**, not during elongation/translocation.

Q: What is a known side effect of clofazimine?

Reddish black skin discoloration. ***Reddish black skin discoloration*** - **Clofazimine** is known to cause a dose-dependent and reversible **reddish-brown to black discoloration** of the skin, conjunctiva, and bodily secretions [1]. - This skin discoloration is a common and characteristic side effect associated with the drug's accumulation in fatty tissues and macrophages. *Hemolytic anaemia* - **Hemolytic anemia** is more commonly associated with drugs like **dapsone**, especially in patients with G6PD deficiency, or rifampicin in rare cases [1], [2]. - It is not a typical or well-known side effect of clofazimine. *Flu like syndrome* - **Flu-like syndrome** is a classic side effect associated with **rifampicin**, another drug used in the treatment of leprosy [2]. - This adverse effect is not characteristic of clofazimine. *Axillary freckling* - **Axillary freckling** (Crowe's sign) is a cutaneous manifestation associated with **neurofibromatosis type 1 (NF1)**. - It is a genetic condition and not a side effect of any medication.

Q: Which of the following is a topical antifungal agent?

Butenafine. ***Butenafine*** - **Butenafine** belongs to the class of **benzylamine antifungals** and is used topically to treat fungal infections such as **tinea pedis (athlete's foot)**, **tinea cruris (jock itch)**, and **tinea corporis (ringworm)**. - Its mechanism of action involves inhibiting **squalene epoxidase**, an enzyme essential for fungal cell membrane synthesis, leading to **ergosterol depletion** and accumulation of squalene, which is toxic to the fungus. *Benzyl benzoate* - **Benzyl benzoate** is primarily used as a **topical scabicide** and **pediculicide**, meaning it targets mites (scabies) and lice. - It works by acting as a **neurotoxin** to these parasites, causing paralysis and death, and is not classified as an antifungal agent. *Brimetenide* - This option appears to be a **misspelling** or **non-existent drug name** in common pharmaceutical contexts. - There is no widely recognized drug with the name **"Brimetenide"** that serves as an antifungal. *Posaconazole* - **Posaconazole** is a **systemic triazole antifungal**, typically administered orally or intravenously for the treatment and prophylaxis of invasive fungal infections in immunocompromised patients. - While it is an antifungal, its primary use is **systemic** rather than topical for treating superficial dermatophyte infections.

Q: What are the active ingredients in Savlon antiseptic?

Cetrimide + Chlorhexidine. ***Cetrimide + Chlorhexidine*** - Savlon antiseptic liquid contains **cetrimide (0.5%)** and **chlorhexidine gluconate (0.1%)** as its active ingredients - This combination provides **broad-spectrum antiseptic activity** with complementary mechanisms - **Cetrimide** acts as a quaternary ammonium compound with surfactant and detergent properties, disrupting bacterial cell membranes - **Chlorhexidine** provides prolonged antimicrobial action by binding to bacterial cell walls and disrupting membrane integrity - This is the **standard formulation** used in Savlon antiseptic liquid *Cetrimide + Chlorhexidine + butyl alcohol* - While cetrimide and chlorhexidine are the active ingredients, **butyl alcohol is not listed as a primary active antiseptic ingredient** in standard Savlon formulation - Butyl alcohol may be present as a **solvent or excipient** but not as an active antiseptic agent *Cetrimide + butyl alcohol* - This combination **omits chlorhexidine**, which is a crucial component for Savlon's antiseptic efficacy - Butyl alcohol is not an active antiseptic ingredient in Savlon *Cetrimide + Cetavlon* - **Cetavlon is a trade name** for preparations containing cetrimide itself, not a separate active ingredient - This option represents a **redundancy** as it essentially lists cetrimide twice under different names

Q: What is the approximate incidence of hepatotoxicity in patients receiving HAART?

10%. ***10%*** - The incidence of **hepatotoxicity** among patients on **HAART** (Highly Active Antiretroviral Therapy) is estimated to be around 10%. - This adverse effect can range from mild, asymptomatic enzyme elevations to **severe liver injury**. *20%* - While hepatotoxicity is a known complication of HAART, an incidence of 20% is generally considered higher than the average reported rates in most studies. - Higher rates might be encountered in specific high-risk populations, such as those with pre-existing liver disease or co-infection with viral hepatitis, but not as a general approximation. *30%* - An incidence of 30% for HAART-induced hepatotoxicity is significantly higher than typically observed and would suggest a higher level of risk than is generally presented in clinical literature. - Such high rates are usually associated with specific, older regimens or very vulnerable patient groups. *40%* - An incidence of 40% is exceptionally high for HAART-induced hepatotoxicity and would indicate a severe and frequent adverse reaction, which is not characteristic of modern HAART regimens. - This figure is not representative of the general incidence in patients receiving contemporary antiretroviral therapy.

Question 1

Ivermectin is the drug of choice for which of the following infections?

Accepted Answer

Onchocerciasis (river blindness caused by Onchocerca volvulus)

Answer

Trichuriasis (whipworm infection)

Answer

Loiasis (African eye worm)

Answer

Trichinosis (pork roundworm infection)

Question 2

Which macrolide is MOST active against Mycobacterium leprae?

Accepted Answer

Clarithromycin

Answer

Erythromycin

Answer

Azithromycin

Answer

Roxithromycin

Question 3

For systemic mycosis, fluconazole is preferred over ketoconazole because of:

Accepted Answer

All of the options

Answer

Lesser side effects

Answer

Greater efficacy

Answer

Longer t1/2

Question 4

Which is the fastest acting anti-malarial drug?

Accepted Answer

Artether

Answer

Chloroquine

Answer

Quinine

Answer

Mefloquine

Question 5

Mechanism of action of Niclosamide is:

Accepted Answer

Inhibition of mitochondrial oxidative phosphorylation

Answer

Inhibition of substrate level phosphorylation

Answer

Inhibition of proton efflux pumps

Answer

Increase production of free radicals

Question 6

Mechanism of action of Linezolid is

Accepted Answer

Inhibits peptide bond formation

Answer

Inhibits 30S ribosomal subunit

Answer

Inhibits 23S ribosome subunit of 50S ribosome

Answer

Inhibits tRNA translocation on the ribosome

Question 7

What is a known side effect of clofazimine?

Accepted Answer

Reddish black skin discoloration

Answer

Hemolytic anaemia

Answer

Flu like syndrome

Answer

Axillary freckling

Question 8

Which of the following is a topical antifungal agent?

Accepted Answer

Butenafine

Answer

Benzyl benzoate

Answer

Brimetenide

Answer

Posaconazole

Question 9

What are the active ingredients in Savlon antiseptic?

Accepted Answer

Cetrimide + Chlorhexidine

Answer

Cetrimide + Chlorhexidine + butyl alcohol

Answer

Cetrimide + butyl alcohol

Answer

Cetrimide + Cetavlon

Question 10

What is the approximate incidence of hepatotoxicity in patients receiving HAART?

Accepted Answer

10%

Answer

20%

Answer

30%

Answer

40%

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?